Barclays Maintains an 'Overweight' on Gilead Sciences (GILD); The Market STRIBILD Will Treat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
FDA Statement on Gilead (GILD) Stribild Approval
August 27, 2012 5:06 PM EDTBelow is the FDA press release for approval of Gilead Sciences Inc. (Nasdaq: GILD) quad pill Stribild for HIV:
The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.
Stribild contains two previously approved HIV drugs plus two new drugs, elvitegravir and cobicistat. Elvitegravir is an HIV integrase strand transfer inhibitor, a drug that interferes with one of the enzymes that HIV needs to multiply. Cobicistat, a... More
Gilead Sciences (GILD) granted FDA approval for Quad pill, Stribild
August 27, 2012 5:02 PM EDTGilead Sciences Inc. (Nasdaq: GILD) granted FDA approval for Quad pill, Stribild, for HIV.... More
